Vietnam warns of food supply disruptions as African swine fever spreads
Vietnam has this year detected 514 outbreaks in 28 out of 34 cities and provinces nationwide, the government said in a statement, adding that the authorities have culled more than 30,000 infected pigs.
"The risk of African swine fever is on a rising trend, negatively affecting the pig farming industry, food supplies and the environment," the government said.
African swine fever has disrupted the global pork market for years. In the worst outbreak over 2018-19, about half the domestic pig population died in China, the world's biggest producer, causing losses estimated at over $100 billion.
The recent outbreaks in Vietnam have prompted Prime Minister Pham Minh Chinh to send an urgent directive to provinces and government agencies this week to deploy measures to curb the disease.
Vietnam in 2023 approved the domestic commercial use of its first home-grown African swine fever vaccines, but officials said the rate of vaccinated pigs remains low.
"Only around 30% of the pigs in my province have been vaccinated," said an animal health official of Quang Ngai province, where infections have been reported over the past few weeks.
"It's not clear why the rate is low - it could either be the issue of vaccine availability, efficiency or cost," said another provincial official, who declined to be named as the person is not authorised to speak to the media.
The agriculture ministry's Department of Animal Health didn't respond to Reuters' request for comment. Calls to AVAC Vietnam JSC, the country's main African swine fever vaccine producer, went unanswered.
AVAC said last month it had sold 3 million vaccine doses in the domestic market and exported 600,000 doses to the Philippines and Indonesia.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 hours ago
- Yahoo
I'm terrified of rabies, my Gen Z daughter fears climate change. Why anxiety is generational
Last month, I was convinced I had rabies. I didn't have any symptoms, or I'd hardly be sitting here writing this, but I was getting occasional intrusive flashes of panic that I was incubating the dread, 100-per cent-fatal virus that can first show symptoms months after exposure. My partner and I had been on holiday in Vietnam a few weeks before. As we were leaving a guesthouse in Ninh Binh, a friendly pet puppy skittered up behind me and lightly nipped my leg through my trousers. Now, there is rabies in Vietnam – 82 people died of it in 2023 – and you don't only get it from street dogs; it lurks even in puppies who seem playful. I weighed the evidence. I hadn't been vaccinated against rabies; most tourists don't bother because the jabs are expensive, and there is a 'post exposure' option if you do interact with a rabid animal. But because the skin on my leg hadn't been broken, I decided I was almost certainly going to be okay, carried on with my holiday, and basically forgot about it. Then, a few weeks after our return, the news was full of the terrible story of Yvonne Ford, a 59-year-old woman from Barnsley, who had died from rabies after being scratched by a puppy while on holiday in Morocco in February. Only scratched! Ford had started experiencing symptoms just two weeks prior to her death on June 11. Upon reading this, I started to worry – albeit in a controlled way. Should I get the 'post infection' set of jabs which would save me from certain death if I had been exposed? Was it worth the not insignificant £500 this would cost? Or should I just live with the very tiny risk? To add to my squirming brain, around this time there was a hostile incident between India and Pakistan, which the media always helpfully refer to as 'nuclear powers.' This brought back my teenage fear of nuclear war, of dying slowly of radiation sickness, as fed by such terrifying 1980s fare as the films Threads and The Day After. It really was Apocalypse Bingo for a while there, earlier this summer. I talked to my daughter, Annabel, 22, about what she made of my paranoias, and we started to explore the subject more deeply. I shared my Generation X fears: nuclear war, Aids – back in the day, at least – and rabies. (Who could forget those scary public information campaigns and screaming, red La Rage posters on cross-channel ferries?) Annabel, who is firmly Generation Z, told me she was worried about her economic future, 'brain aneurysms and freak deaths – I think this definitely comes from reading too much health journalism,' but most of all, climate change. 'Fears about climate change do occasionally keep me up at night,' she said. 'The heatwaves have been making me worried about the coming decades. It is clearly already happening. I think due to modern life we all forget how reliant we are upon the environment. Although the anxiety maybe isn't productive, I do think we should all be more concerned about climate change.' Why anxiety sticks with us I asked Owen O'Kane, a psychotherapist and the author of the bestselling book Addicted to Anxiety, what he made of all this. To a certain extent, the 'flavour' of our fears is due to what was making headlines at a formative period in our lives, he believes. 'Fashions change and we go through phases, your experience as an early adult stays with you,' he says. 'News headlines certainly don't help. The people who write them go for the worst-case scenario, the most catastrophic outcome. If you are anxious by nature, your 'anxious self' will gravitate towards these headlines.' If you tend towards anxiety, these more dramatic incidents are likely to affect you compared with an individual who is more sanguine. 'Anxious people are responsible people and they care deeply about things,' says O'Kane. 'They have a healthy altruistic core.' The problem, however, is that there's a risk anxiety can affect your life in a negative way. 'Your anxiety is like a watch guard, looking for a potential threat, and you might suddenly fixate on this threat,' says O'Kane. 'For example, a teenager might see a photo of a field of fire, and start worrying about climate change after a period of not thinking about it.' At heart, says O'Kane, anxiety is all about how much a person can tolerate the uncertainty of everyday life. 'To be worried is useful and has a function, to some degree,' he says. 'But it becomes a problem if we become obsessive, or avoid going out, for example. Every person has to do a cost-benefit analysis – where the price is not leading your life, and you become 'addicted' to your anxiety.' These days, says O'Kane, many people are 'frightened of our own shadow. 'The presentation and triggers are different, but these existential fears are actually our psyche asking fundamental questions: 'Will I get ill?', 'Will I die?', 'Will anyone help me?' 'Will I cope?'' And for our children's generation, the triggers are everywhere. 'People who are now in midlife didn't have social media,' says O'Kane. 'There was less exposure to world events. Yes, we knew there were wars and starvation and plane crashes; we were not unaware of these. But young people have a more elevated awareness of what's going on globally. It's not surprising that there are heightened levels of anxiety in Generation Z.' How social media fuels modern fears Annabel agrees with this analysis. 'Most of my fears are because of the news and social media, which allow little nuggets of anxiety to interrupt your day,' she says. 'Your phone pops up and it's another thing to be worried about, because that's what we engage with.' O'Kane suggests that anxieties can fluctuate, both in a negative way – in that they become harmful phobias – but also in a positive way, in that you can learn to manage and overcome them. I certainly concur with this: my teens and 20s were a mass of health anxieties, usually involving dread neurological diseases, all without a logical explanation. As I grew up, I learnt to keep a lid on these worries and defuse them. So, how did I resolve my rabies scare? First of all, I looked up the statistics of how many people had died of rabies in the UK after a foreign trip: six people between 2000 and 2024. I spoke to my sister-in-law, a GP, who reiterated my chance of contracting the virus was infinitesimal. I then texted the guesthouse in Vietnam, who told me the puppy had been vaccinated against rabies and was healthy. (I have to assume they were telling the truth.) As I received this reply, I was looking at my phone while crossing a road and almost got hit by a car. When I related the above to O'Kane, I was thrilled to have passed his 'healthy response' test. 'The situation was that you were bitten by a dog and there was rabies in the area,' he says. 'It's not dissimilar to how people felt during Covid. I wouldn't describe this as an irrational fear, but a 'situational one'. 'The context of your worry was normal and your parameters went up, you identified the trigger,' he says. 'Someone less prone to worry than you would have made the decision this was low risk and not worried at all afterwards. But you did the healthy thing for you – looked at the broader evidence, weighed it up, and let it go. You were able to acknowledge you could tolerate the worry. Someone more prone to worry would have been googling furiously, or have gone for the vaccinations.' O'Kane is at pains to point out that not all anxieties should be dismissed. 'I'm not saying you should tolerate all uncertainty, and there are useful, functional worries,' he says. 'For example, if you've had unsafe sex with someone you know is HIV positive, you should take the sensible medical approach and seek treatment.' And in less critical situations, we can lower our exposure to worrying material. 'I've gone off social media, and I'm feeling a bit better about everything,' says Annabel. 'It was overwhelming though, because there's so much online encouragement to optimise and do better – very Gen Z.' Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more. Solve the daily Crossword
Washington Post
17 hours ago
- Washington Post
FDA to announce crackdown on synthetic substance derived from kratom
Health officials plan to announce measures Tuesday to crack down on an opioid-like substance found in tablets, gummies and drinkable shots commonly sold in convenience stores. The Department of Health and Human Services said in an advisory that it is targeting potentially dangerous products made of 7-OH, a potent substance synthesized from a compound in the kratom leaf, which grows on trees native to Southeast Asia. The Food and Drug Administration, researchers and kratom companies have grown increasingly alarmed by the rise of 7-OH products they say are distinct from all-natural plant teas and powders.
Yahoo
17 hours ago
- Yahoo
North America Clinical Trials Market Forecast and Company Analysis Report 2025-2033 Featuring ICON, Wuxi AppTec, SGS, Syneos Health, PRA Health Sciences, Pfizer, IQVIA, and Medpace
The North America Clinical Trials Market is projected to grow from US$ 20.07 billion in 2024 to US$ 33.91 billion by 2033, registering a CAGR of 6.00% from 2025 to 2033. Key drivers include the increasing demand for novel treatments, rising prevalence of chronic conditions like COVID-19, diabetes, and various cancers, as well as supportive government R&D investments. The U.S. leads with robust infrastructure, top-notch research facilities, and significant technological advancements such as AI and decentralized trials. However, challenges persist with high operational costs and regulatory complexities. The market is vibrant, driven by rising clinical trial investments in sectors like oncology and enabled by innovative technologies, making it a promising field despite ongoing hurdles. North American Clinical Trials Market Dublin, July 29, 2025 (GLOBE NEWSWIRE) -- The "North America Clinical Trials Market Size and Forecast Report 2025-2033" report has been added to North America Clinical Trials Market is expected to reach US$ 33.91 billion by 2033 from US$ 20.07 billion in 2024, with a CAGR of 6.00% from 2025 to 2033. This is explained by longer clinical trial cycles, the demand for new treatments, and an increase in viral disorders as COVID-19 and diabetes, as well as advantageous government R&D spending. The growing need for novel medicines in a variety of therapeutic areas, including neurology, cardiology, and oncology, is the main factor propelling the North American clinical trials market's constant expansion. As a market leader, the United States enjoys the advantages of strong infrastructure, top-notch research facilities, and substantial investments in innovative healthcare. Drug development procedures are becoming faster and more efficient because to technological developments like big data, artificial intelligence, and decentralized clinical trials. Government financing and support for clinical research also contribute to the market's expansion. Nonetheless, the sector is still affected by issues including regulatory barriers, trouble recruiting patients, and expensive trial operating expenses. The market is nevertheless vibrant and is anticipated to continue evolving in spite of these market will expand quickly as a result of the growing number of clinical trials in North America, the pharmaceutical industry's expensive R&D costs, and the rising incidence of illnesses. Clinical trials for new or uncommon diseases are anticipated to benefit from the diverse disease profiles that are found to be growing with time due to the growing population in the North American region. Therefore, biopharmaceutical companies would be encouraged to increase their investment in clinical trials for a particular disease segment based on the number of patients with that of September 2022, there were over 13,323 ongoing clinical studies in various stages for cancer indications in the US, according to the US National Library of Medicine. Over the past few years, pharmaceutical corporations have likewise been spending more and more on research and development (R&D). This was mostly caused by a large number of patents expiring, which leaves many pharmaceutical companies with no choice except to create new medications. As a result, businesses are investing more in R&D to speed up the creation of medications through clinical trials, which will increase the market as a Drivers for the North America Clinical Trials Market Rising Prevalence of Chronic DiseasesOne of the main factors propelling the North American clinical trials market's expansion is the growing incidence of chronic illnesses including diabetes, cancer, and cardiovascular disorders. Clinical trials are being conducted by pharmaceutical corporations and research institutions due to the growing demand for new treatments and therapies as these diseases proliferate. These studies are essential for assessing the efficacy and security of possible treatments. Clinical trials are crucial for expanding medical knowledge and enhancing patient outcomes since chronic diseases frequently call for long-term management and innovative treatment choices. An older population, which is more likely to suffer chronic illnesses, supports this trend and increases the need for ongoing clinical research and innovative therapy in TechnologyTechnological developments are drastically changing the clinical trials environment in North America. Clinical study design, management, and execution are being improved by emerging technologies including artificial intelligence (AI), machine learning (ML), and big data analytics. These technologies aid in the real-time analysis of massive volumes of trial data, the more accurate identification of qualified applicants, and the prediction of patient outcomes. They thereby shorten trial durations, cut down on mistakes, and enhance decision-making. AI and ML are also being used to remotely monitor patient adherence and optimize protocol design, which lowers costs and increases trial efficiency. These developments make technology a potent growth engine in the dynamic clinical research environment since they not only speed up drug development but also increase trial success Investment in Oncology ResearchOne of the main factors propelling the growth of the clinical trials market is the rising incidence of cancer in North America, which has greatly increased funding for oncology research. The creation of novel cancer treatments is receiving a significant amount of support from public and private institutions as well as pharmaceutical firms. Clinical trials focusing on cancer, such as immunotherapies, targeted medicines, and personalized medical methods, have increased as a result of this financial boom. Research efforts have been sped up by the need to find efficient treatments and raise survival rates, which has prompted quicker trial initiation and increased cooperation between sponsors and research institutes. Since cancer is still one of the top causes of mortality, the region's clinical trial activity is growing in scope and size due to the strong emphasis on oncology in the North America Clinical Trials Market High Operational CostsOne major issue facing the clinical trials sector in North America is high operating costs. Significant costs are associated with conducting a clinical trial, such as hiring highly qualified personnel, investing in cutting-edge technology, building out the facility, adhering to regulations, and continuously gathering and tracking data. Complex trial designs, multi-site coordination, and longer study durations can all result in further increases in these expenses. Financial limitations can make it difficult for smaller biotech companies and research institutes to start or continue trials, frequently forcing them to rely on collaborations or outside funding. There is still a lot of pressure to strike a balance between cost effectiveness, data quality, and legal requirements. The cost of trials only goes up as they get more creative and customized, which is a major obstacle to larger research and development ComplexitiesOne of the biggest obstacles facing the clinical trials sector in North America is the complexity of regulations. To guarantee the safety and effectiveness of novel medications and therapies, organizations such as the U.S. Food and Drug Administration (FDA) implement strict and ever-changing regulations. Although these rules are necessary, following them can cause delays in trial approvals and raise compliance expenses dramatically. The procedure, which can be time- and resource-intensive, entails thorough documentation, ethical evaluations, and adherence to stringent criteria. Conducting multinational or multi-site studies also adds another level of complexity because different regulatory requirements in different locations need to be carefully maintained. These elements may cause delays in the start of trials, cause schedule disruptions, and increase the administrative load on sponsors and research institutions. Key Players Analyzed: Overviews, Key Persons, Recent Developments, Revenue ICON Plc Wuxi AppTec SGS SA Syneos Health PRA Health Sciences Inc Pfizer Inc. IQVIA Medpace Stryker Corporation Zimmer Biomet Holdings Orthofix Medical Inc. NuVasive Inc. Globus Medical Inc. Bejo Zaden BV Corteva Agriscience Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $20.07 Billion Forecasted Market Value (USD) by 2033 $33.91 Billion Compound Annual Growth Rate 6.0% Regions Covered North America Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. North America Clinical Trials Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share6.1 By Phases6.2 By Indications6.3 By Study Designs6.4 By Countries7. Phases7.1 Phase 17.2 Phase 27.3 Phase 37.4 Phase 48. Indications8.1 Autoimmune/Inflammation8.2 Pain management8.3 Oncology8.4 CNS Condition8.5 Diabetes8.6 Obesity8.7 Cardiovascular8.8 Others9. Study Designs9.1 Interventional9.2 Observational9.3 Expanded Access10. Countries10.1 United States10.2 Canada10.3 Mexico10.4 Rest of North America11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Rivalry11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threat13. Key Players AnalysisFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment North American Clinical Trials Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
